Cargando…

Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse

Anaplastic Lymphoma Kinase (ALK) is a transmembrane receptor kinase that belongs to the insulin receptor superfamily and has previously been shown to play a role in cell proliferation, migration and invasion in neuroblastoma. Activating ALK mutations are reported in both hereditary and sporadic neur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lindi, Humphreys, Angharad, Turnbull, Lisa, Bellini, Angela, Schleiermacher, Gudrun, Salwen, Helen, Cohn, Susan L., Bown, Nick, Tweddle, Deborah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349989/ https://www.ncbi.nlm.nih.gov/pubmed/27888620 http://dx.doi.org/10.18632/oncotarget.13541

Ejemplares similares

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

Detection of tumor ALK status in neuroblastoma patients using peripheral blood
por: Combaret, Valérie, et al.
Publicado: (2015)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Factors associated with recurrence and survival length following relapse in patients with neuroblastoma
por: Basta, Nermine O, et al.
Publicado: (2016)

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma
por: Southgate, Harriet E. D., et al.
Publicado: (2020)

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma
por: Herd, Fiona, et al.
Publicado: (2019)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines
por: Yang, Qiwei, et al.
Publicado: (2010)

Use of Optical Genome Mapping to Detect Structural Variants in Neuroblastoma
por: Barford, Ruby G., et al.
Publicado: (2023)

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
por: Decock, Anneleen, et al.
Publicado: (2015)

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
por: Chen, Lindi, et al.
Publicado: (2012)

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015)

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma
por: Liu, Tingting, et al.
Publicado: (2021)

Presence Of Cancer-Associated Fibroblasts Inversely Correlates With Schwannian Stroma In Neuroblastoma Tumors
por: Zeine, Rana, et al.
Publicado: (2009)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells
por: King, David, et al.
Publicado: (2021)

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
por: Chlenski, Alexandre, et al.
Publicado: (2010)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
por: Berko, Esther R., et al.
Publicado: (2023)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018)

Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment
por: Mazot, Pierre, et al.
Publicado: (2012)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

5′ ALK Amplification in Neuroblastoma: A Case Report
por: Akhavanfard, Sara, et al.
Publicado: (2021)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
por: Schleiermacher, G, et al.
Publicado: (2011)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
por: Cervantes-Madrid, Diana, et al.
Publicado: (2019)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_83u5uv95otfoqnvn3dn4072ibi